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Abstract
Background: Non-Hodgkin lymphoma (NHL) is the most common AIDS-related malignancy in developed countries. An
elevated risk of developing NHL persists among HIV-infected individuals in comparison to the general population despite
the advent of effective antiretroviral therapy. The mechanisms underlying the development of AIDS-related NHL (A-NHL) are
not fully understood, but likely involve persistent B-cell activation and inflammation.
Methods: This was a nested case-control study within the ongoing prospective Multicenter AIDS Cohort Study (MACS).
Cases included 47 HIV-positive male subjects diagnosed with high-grade B-cell NHL. Controls were matched to each case
from among participating HIV-positive males who did not develop any malignancy. Matching criteria included time HIV+ or
since AIDS diagnosis, age, race and CD4+ cell count. Sera were tested for 161 serum biomarkers using multiplexed bead-
based immunoassays.
Results: A subset of 17 biomarkers, including cytokines, chemokines, acute phase proteins, tissue remodeling agents and
bone metabolic mediators was identified to be significantly altered in A-NHL cases in comparison to controls. Many of the
biomarkers included in this subset were positively correlated with HIV viral load. A pathway analysis of our results revealed
an extensive network of interactions between current and previously identified biomarkers.
Conclusions: These findings support the current hypothesis that A-NHL develops in the context of persistent immune
stimulation and inflammation. Further analysis of the biomarkers identified in this report should enhance our ability to
diagnose, monitor and treat this disease.
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Introduction
Non-Hodgkin lymphoma (NHL) is the most common AIDS-
related malignancy in developed countries [1], where it accounts
for 23–30% of AIDS-related death [2–4]. Although NHL also
affects HIV-uninfected individuals, the risk of developing AIDS-
associated NHL (A-NHL) is estimated to be 60 times greater in
HIV-infected (HIV+) persons [5,6]. A recent study regarding the
incidence of AIDS-related cancer in the years prior to and during
widespread administration of highly active antiretroviral therapy
(HAART) indicated that while HAART implementation is
associated with a reduction in NHL rates among HIV+ persons,
rates of A-NHL development remain significantly higher than
those observed in uninfected populations [7]. Immunosuppression
of any type appears to be a major risk factor for NHL
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development, with duration of HIV infection and nadir CD4-
positive (CD4+) T cell counts positively and inversely associated
with the risk of A-NHL, respectively [8,9]. The incidence of
primary central nervous system lymphoma (PCNSL), a less
prevalent subtype of NHL associated with immune deficiency,
has been reported to be over 1000 times higher in persons with
AIDS compared to the general population [10,11], although
recent evidence suggests that this incidence is declining dramat-
ically with the advent of HAART [12].
The precise pathogenic mechanism underlying A-NHL devel-
opment is a current focus of intense scrutiny, and several basic
themes have emerged. Immune deficiency appears to contribute to
the development of A-NHL through the loss of T-cell mediated
control over B-cell proliferation. This mechanism appears to be
particularly important in the development of Epstein-Barr virus
(EBV)-positive A-NHL (reviewed in [13]). The persistently
elevated incidence of A-NHL despite the advent of HAART
argues for additional pathogenic mechanisms including hyper-
activation of B-cells. Chronic B-cell hyperactivation associated
with genetic abnormalities due to EBV or human herpesvirus-8
(HHV-8) infection, c-MYC and BCL-6 rearrangements, RAS or
p53 mutations, and 6 q deletions is believed to play a role in A-
NHL [6,14,15]. Direct integration of HIV into the genome of
malignant B-cells has not been observed experimentally, however
persistent antigenic stimulation of B-cells during HIV infection
may promote hyperactivation and transformation [16–19].
Another proposed mechanism suggests that HIV-infected macro-
phages contribute stimulatory signals in order to create a
microenvironment permissive to malignant B-cell growth [20].
The proposed pathogenic pathways underlying the develop-
ment of A-NHL suggest a complex network of interactions
between various components of the immune system. Cytokines
and other inflammatory mediators represent the chief means by
which these components mediate those interactions. A number of
groups have evaluated serum biomarkers in an effort to more fully
characterize the dysregulated cytokine signalling underlying the
immunological mechanisms at work in the development of A-
NHL. A number of proteins involved in B-cell activation,
stimulation and other inflammatory functions have been impli-
cated by the findings of those groups including: IL-6 [21,22], IL-10
[21–23], IP-10 [22], neopterin [22], immunoglobulin free light
chains [22], sCD30 [21,24], sCD23 [21,25], sCD44 [26], CRP
[21], CXCL13 [27,28] and TNFa [22]. Many of these proteins
were observed at elevated serum levels in subjects prior to the
diagnosis of A-NHL with a lead time ranging from several months
to several years [21,23,24,26]. These findings suggest that the
analysis of serum biomarker levels in HIV+ individuals may help
in risk assessment strategies for NHL or in the development of
prophylactic or preventive measures through an improved
understanding of the early events of malignancy.
In the current study, we sought a broad evaluation of serum
biomarkers that could possibly be associated with the development
of NHL in HIV+ individuals. To that end, multiplexed bead-based
immunoassays were utilized in the evaluation of serum levels of
161 proteins in subjects diagnosed with A-NHL and controls.
Materials and Methods
Ethics Statement
All subjects involved in this study were over the age of 18 and
provided written informed consent. Specimen collection proce-
dures were approved by the respective Institutional Review Board
(IRB) at each collection site: Johns Hopkins Medicine IRB,
Northwestern University IRB, University of California, Los
Angeles IRB, University of Pittsburgh IRB. The current study
was approved by the University of Pittsburgh IRB.
Study Population
The Multicenter AIDS Cohort Study (MACS) is an ongoing
prospective study of the natural and treated histories of HIV-1
infection in homosexual and bisexual men conducted at sites
located in Baltimore, Chicago, Pittsburgh and Los Angeles [29]. A
total of 6,972 men have been enrolled. For the current analysis we
obtained archived sera from HIV+ subjects diagnosed with high
grade B-cell NHL (according to the MACS data repository) for
which serum was available either immediately prior to (#12
months, n = 37) or shortly after (#3 months, n = 10) NHL
diagnosis. For each case, a single matched control was identified
from among HIV+ participants who did not develop any
malignancy. Cases for which NHL was AIDS-defining (n = 25)
were matched to controls who had not yet received an AIDS
diagnoses at the time of blood collection, based on duration of
HIV+ status (+/21 year). Cases for which NHL developed
subsequent to an AIDS diagnosis (n = 22) were matched to
controls who had developed an AIDS-defining opportunistic
infection (OI), based on time since AIDS diagnosis (+/21 year).
Matching criteria also included age (+/25 yrs) and absolute
CD4+ T cell count (+/2100 cells/mm3) at the time of blood
collection in the case or matched visit in the control, and race
(white or black). Following matching, a total of 49 cases and 49
controls were selected. Sera obtained for three subjects (2 cases, 1
control) were not evaluable due to insufficient volume or
hemolysis. In the resulting groups of 47 cases and 48 controls
(Table 1), age, race distribution, CD4+ T cell counts, and duration
of HIV positivity did not differ significantly (p.0.05), reflecting
the original matching criteria. The final experimental cohort
included 46 matched pairs. 46 of the cases included in the current
study overlap with those used in recent studies utilizing the MACS
cohort [21,27,30]. In the majority of overlapping cases, the date of
serum collection for the current study was closer to or after the A-
NHL diagnosis date, compared to previous studies, as determined
by the specific selection criteria. Information on NHL subtypes
was obtained from the MACS data repository. HIV viral load
values obtained at time of blood draw for biomarker analysis were
available from the MACS data repository for 36 case and 22
control subjects. Viral load values were not utilized for matching
but were utilized in subsequent biomarker analyses. Information
on antiretroviral therapy was obtained from the MACS data
repository for each case and control. HAART regimens were
defined according to the DHHS/Kaiser guidelines [31]. Subjects
were classified as current recipients if they received HAART at the
same visit as their blood draw or during the interim time in
between this visit and the previous MACS visit. Subjects were
classified as former recipients if they received HAART prior to but
not during this time period. Subjects classified as never receiving
HAART may have received other antiretroviral therapy not
classified as HAART. The characteristics of the study population
are presented in Table 1.
Sources of bead-based immunoassays
A combination of 161 bead-based immunoassays for a diverse
set of serum biomarkers available on the Luminex platform was
utilized in this study (Table 2). This list of biomarkers was
assembled based on a literature review of proteins and families of
proteins of interest in all areas of HIV and NHL research.
Biomarkers were selected from this list on the basis of suitable
immunoassay availability. A total of 29 multiplexed and individual
assays were utilized (Table S1). Bead-based immunoassays
Immmunological Biomarkers in AIDS-Related Non-Hodgkin Lymphoma
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targeting ErbB2, EGFR, Cytokeratin 19(Cyfra 21-1), mesothelin
(MSLN), AFP, CA 72-4, MICA, SCC, HSP 70, EPCAM, PSA,
transthyretin (TTR), angiostatin (AS), thrombospondin (TSP),
endostatin (ES), TgII, HE4, CA 15-3, CA 125, CEA, and
Kallikrein 10 (Klk10) were developed by the UPCI Luminex Core
Facility according to strict quality control standards[32]. Assays for
MMP 1, 2, 3, and 7 and TIMP 1–4 were obtained from R&D
Systems (Minneapolis, MN). Assays for PDGF-BB, RANTES,
SCGF-B, and NGF were obtained from Bio-Rad (Hercules, CA).
Assays for HSP27, IL-1a, IL-1b, IL-3, IL-5, IL-7, IL-8, IL-12p40,
IL-15, IL-17, TNF-a, IFNa, GM-CSF, MCP-1, MCP-3, MIP-1a,
MIP-1b, IP-10, Eotaxin (CCL11), RANTES, DR5, EGF, FGFb,
G-CSF, HGF, VEGF, and GROa were obtained from Life
Technologies/Biosource (Grand Island, NY). All other assays were
obtained from Merck/Millipore (Durmstadt, Germany). All
commercial immunoassays were performed according to manu-
facturer’s protocols while UPCI Luminex Core Facility assays
were performed as previously described [32,33].
Collection and statistical analysis of biomarker data
Each serum sample was analyzed for each multiplex immuno-
assay using the Bio-Plex suspension array system and the Bio-Plex
Manager software (version 4.1) (Bio-Rad Laboratories, Hercules,
CA). For each analyte, 100 beads were analyzed and the median
fluorescence intensity was determined. Analysis of serum sample
biomarker data was performed using five-parameter logistic curve
fitting to standard analyte values. A number of samples fell below
lower limit of extrapolation of the Bio-Plex Manager software for
certain analytes and were therefore reported as out of range low
(OOR ,). The percentages of cases and controls classified in this
manner for each analyte are listed in Table S2. Observed
concentration values were assigned to each of the OOR, samples
by manual extrapolation using the curve fitting parameters
determined by the Bio-Plex software. Hence, no samples were
excluded from the analysis on the basis of undetectability. The
entire biomarker dataset has been deposited with the Center for
Analysis and Management of Multicenter AIDS Cohort Study
(CAMACS).
Biomarker distributions among the A-NHL and control groups
were analyzed using both parametric and non-parametric
statistical tests. In each analysis the minimum level of significance
was p,0.05. For the parametric analysis, exact conditional logistic
regression was performed on the biomarker data obtained for the
A-NHL and control groups (n = 46 matched case-control pairs).
The results were further analyzed using the Bonferroni Step-Down
(Holm) correction for multiple comparisons. For the non-
parametric analysis, the Mann-Whitney U test was utilized on
data from 47 cases and 48 controls without regards to matching.
Here, the False Discovery Rate (FDR) was controlled at 5%
according to the method described by Benjamini and Hoch-
berg[34]. Biomarker variations among several subtypes of NHL
were evaluated using a one-way ANOVA with Tukey’s multiple
Table 1. Characteristics of Study Population.
A-NHL Cases (n=47) Controls (n=48)
Age (years), range (median) 25–56 (42) 26–56 (40)
Race, n (%)
White 46 (98) 47 (98)
Black 1 (2) 1 (2)
CD4+ T Cell Count (cells/mm3), range (mean) 7–788 (146) 6–794 (193)
Receiving HAART [31], n (%)
Current 6 (13) 5 (10)
Former 1 (2) 1 (2)
Never 38 (81) 42 (87.5)
Unknown 2 (4) 0 (0)
HBV Serology, n (%)
Positive 41 (87) 42 (87.5)
Negative 3 (6) 6 (12.5)
Unknown 3 (6) 0 (0)
HHV-8 Serology, n (%)
Positive 28 (57) 35 (73)
Negative 9 (19) 9 (19)
Unknown/Indiscriminate 10 (21) 4 (8)
NHL Subtype, n (%)
B-cell Diffuse 20 (43)
CNS 11 (23)
BL, BL-like 7 (15)
NHL, NOS 6 (13)
Other 3 (6)
HAART – highly active antiretroviral therapy; HBV/HHV-8 status obtained at time of blood draw; CNS – central nervous system; BL – Burkitt’s lymphoma; NOS – not
otherwise specified.
doi:10.1371/journal.pone.0099144.t001
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comparison test. Correlations between biomarker levels and HIV
viral load were evaluated using the Spearman test for correlation.
Pathway Analysis
The Ingenuity Pathway Analysis (IPA) software package
(Ingenuity Systems, Inc., Redwood City, CA) was used to examine
pathways and interactions associated with the most promising
biomarkers identified in our analysis described above. Additional
serum biomarkers demonstrating associations with A-NHL in
previous reports, which were not measured in the current
investigation, were also included in this analysis. The list of
additional biomarkers included IL-6 [21], IL-10 [21,23,30],
sCD30 [21,24], sCD23 [21], sCD44 [26], sCD27 [21], CRP
[21], and CXCL13 [27,28]. Some of these reports utilized a
number of overlapping MACS NHL cases as described above.
The IPA analysis identifies interactions based solely on the identity
of the biomarkers inputted into the software and did not utilize
biomarker concentrations.
Results
Biomarker alterations among A-NHL cases and controls
The non-parametric analysis of biomarker distributions among
all cases and controls revealed that 19 out of the 161 biomarkers
tested were significantly altered in the comparison of A-NHL cases
and controls (Table 3). Among these 19 significant biomarkers,
two (MMP-9, OC) were observed to be decreased in the A-NHL
group in comparison to the controls, while the remaining 17 were
increased. The parametric statistical analysis on 46 case-control
pairs yielded a larger list of 37 significant biomarkers (Table 4)
which included all but two biomarkers (FBN, A1A) identified in
the non-parametric analysis. Among the 37 significant biomarkers
in this analysis, four (OC, ApoA1, MMP-9, IGFBP-6) were
observed to be decreased in the A-NHL subjects relative to the
control groups, while the remaining 33 biomarkers were all
increased. All trends in biomarker alterations between the cases
and controls were consistent among the non-parametric and
parametric analyses despite the differential use of median and
mean values, respectively, and slightly different numbers of
subjects. The application of the Bonferroni Step-down (Holm)
correction to our parametric analyses yielded a restricted list of
three biomarkers (IL-11, CXCL11, IL-29) which were observed to
be highly significant (Table 4). A comparison of the non-
parametric and parametric analyses prior to Bonferroni correction
(overlap between tables 3 and 4) yielded a consensus list of 17
serum biomarkers significantly altered in the comparison of the A-
NHL and control groups. The consensus list included cytokines/
chemokines (CCL19, CXCL11, MCP-2, MIP-1d, IFNa, IL-11,
IL-29, IP-10, M-CSF, sIL-1R1), acute phase proteins (C3, HPN,
SAA, SAP), tissue remodeling factors (MMP-9, TIMP-1), and the
bone metabolic factor OC.
Correlation with HIV viral load
Biomarker measurements from the A-NHL and control groups
were combined in order to identify correlations between specific
biomarkers and HIV viral load. Among the complete panel of 161
biomarkers, a total of 17 biomarkers exhibited significant
correlations with HIV viral load (data not shown). Most notably,
11 of the significantly correlated biomarkers were among the
consensus biomarkers described above, and are presented in
Table 5. With the notable exception of MMP-9, each of the
significant correlations among the consensus biomarkers was
consistent with HIV progression, i.e., higher biomarker concen-
trations were correlated with higher HIV viral load.
A-NHL subtype specific biomarker alterations
Each of the 17 consensus biomarkers were evaluated in case
subsets including subjects diagnosed with B-cell diffuse, CNS, or
Burkitt’s Lymphoma (BL)/BL-like NHL using pair-wise one-way
ANOVA. As this analysis included cases only, biomarker levels
were normalized to CD4 counts prior to ANOVA to account for
variations in disease severity. In a comparison of BL/BL-like and
CNS NHL cases, OC and Timp-1 were significantly different with
p,0.05. In the comparison of CNS and B-cell diffuse NHL cases,
three significant alterations were observed including OC, SAP and
Timp-1 (data not shown). In each comparison, significantly
Table 2. Complete List of Evaluated Biomarkers.
Tumor Markers AFP, CA 15-3, CA 19-9, CA125, CA72-4, CEA, EPCAM, HE4, Kallikrein-10 (Klk10), Mesothelin (MSLN), PSA, squamous cell carcinoma antigen
(SCC), tissue transglutaminase (Tgll)
Growth/Angiogenesis
Factors
Angiostatin (AS), EGF, EGFR, Endostatin (ES), ErbB2, FGFb, HGF, IGFBP 1-7, NGF, PDGF-BB, SCGF-B, sVEGF-1, sVEGFR2-3, TGFa,
Thrombospondin (TSP)
Hormones ACTH, Cortisol, FSH, GH, Insulin, LH, Prolactin, PTH, TSH
Apoptosis Factors Cyfra 21-1, Fas, FasL
Cytokines/Chemokines/
Receptors
6CKine/CCL21, CTACK/CCL27, DR5, ENA-78/CXCL5, EOTAXIN-1 (CCL11), EOTAXIN-2/CCl24/MPIF-2, EOTAXIN-3/CCL26, FLT3, Fractalkine,
GCP-2/CXCL6/LIX, G-CSF, GM-CSF, GROa, HCC-1/CCL14a, I-309/CCL1, IFNa, IL-1a, IL-1b, IL-3,5,7,8,11, IL-12p70, IL-12p40, IL-15-17,20, IL-28a,
IL-29, IL-33/NF-HEV(mat), IP-10, I-TAC/CXCL11, LIF, Lymphotactin, MCP-1-4, M-CSF, MDC, MIF, MIP-1a, MIP-1b, MIP-1d/MIP-5/CCL15, MIP-
3a/CCL20, MIP-3b/CCL19, MIP-4, MPO, NAP-2/CXCL7, RANTES, sCD40L, SCF, SDF-1a+b/CXCL12, sIL-1Rl,II, sIL-4R, sIL-6R, sRAGE, sTNF –Rl,
sTNF-Rll, TARC/CCL17, TNFa, TNFb, TPO, TRAIL/TNFSF10, TSLP
Adhesion Molecules E-Selectin, Fibronectin (FN), sICAM, sVCAM
MMPs/TIMPs MMP-1-3, 7-9, 12,13, TIMP-1-4
Bone Factors Osteoprotegerin (OPG), Osteocalcin (OC), Osteopontin (OPN), RANKL
Apolipoproteins Apo A1, Apo Clll, Apo E
Acute Phase Proteins a1-Antitrypsin (A1A), a2-Macroglobulin, Complement C3 (C3), Complement C4, Complement Factor H (CFH), Fibrinogen (FBN),
Haptoglobin (HPN), human serum albumin (HSA), transthyretin (TTR), serum amyloid A (SAA), serum amyloid P (SAP)
Adipokines Adiponectin, aPAI-1, Leptin, Resistin, tPAI-1
Other HSP 70, Involucrin, pan-Keratin (1,10,11), Keratin-6, LPS, MICA, PEDF
doi:10.1371/journal.pone.0099144.t002
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elevated levels of each biomarker were observed in CNS NHL
relative to the other subtypes.
Pathway Analysis
The IPA software package was first used to analyze the
consensus list of 17 serum biomarkers identified in this study. The
top biological functions associated with the consensus list included
Cellular Movement (14/17 molecules, p = 1.6610214–1.961023),
Cell-to-Cell Signaling and Interaction (13/17 molecules,
p = 1.4610210–1.961023), Hematological System Development
and Function (14/17 molecules, p = 1.6610214–1.961023), and
Immune Cell Trafficking (14/17 molecules, p = 1.6610-14–
1.961023). Interactions between molecules were then examined
for each biomarker included in the consensus list and several
biomarkers examined in association with A-NHL in previous
studies including IL-6, sCD30, IL-10, sCD23, sCD44, sCD27,
CRP, CXCL13, and IgE. An extensive array of interactions within
and among the two lists of biomarkers was identified (Figure 1).
With the exceptions of MIP-1d, IFNa, and OC, each of the newly
identified biomarkers was found to interact with at least one
previously identified biomarker. MMP-9 demonstrated the most
extensive network of interactions including six interactions with
other newly identified biomarkers and four interactions with
previously identified biomarkers. Other newly identified biomark-
ers demonstrating more than five interactions included IP-10 (7
new/2 previous), M-CSF (3 new/4 previous), sIL-1R1 (4 new/2
previous), TIMP-1 (3 new/3 previous), C3 (3 new/3 previous), and
SAP (2 new/4 previous). Many of the previously identified
biomarkers also displayed numerous interactions within and
among the groups.
Discussion
A diverse analysis of serum proteins in samples collected just
before or after the time of A-NHL diagnosis identified a consensus
list of potential A-NHL biomarkers, assembled through rigorous
statistical analysis, which included various inflammatory media-
tors, acute phase proteins and tissue remodeling agents. Although
our panel of candidate biomarkers was considerably large and
composed primarily of inflammatory and immune-modulating
factors, a relatively small subset was observed to be altered,
suggestive of some level of specificity for A-NHL with respect to
HIV+ status or other AIDS defining illness. Increased levels of a
number of circulating proteins have previously been reported up
to 3–5 years prior to the diagnosis of A-NHL including IL-6, IL-
10, sCD23, sCD27, sCD30, sCD44, IgE, CRP, and BCA-1/
CXCL13[21–24,26–28,30,35,36]. While the current study did not
include a direct examination of these biomarkers, an analysis of
biomarker interactions revealed a number of mechanistic links
between and among those biomarkers identified both previously
and currently (Figure 1). The most recent longitudinal study of A-
NHL risk in HIV+ persons identified IP-10 and TNFa, in addition
to several others, as potential biomarkers [22]. The current cross-
sectional analysis evaluated both of these biomarkers but found
only IP-10 to be significantly altered.
The conservative use of the Bonferroni correction as part of our
parametric statistical analysis suggested that serum levels of IL-11,
CXCL11 and IL-29 demonstrated the strongest associations with
A-NHL in our study. These findings further agree with the
hypothesized immune activating origins of this disease. IL-11, an
important mediator of hematopoiesis, has been investigated as an
Table 3. Serum biomarker levels in AIDS-NHL subjects and controls evaluated by Non-parametric Statistics.
A-NHL (n=47) Control (n = 48) A-NHL vs. Control
Biomarker Median IQR Median IQR MWU p value (trend)
CCL19/MIP-3b 238 133 197 112 6.89E-03 (I)
C3{ 111 53.7 80.9 33.0 1.52E-03 (I)
CXCL11/I-TAC 266 393 132 128 9.31E-05 (I)
FBN{ 161 151 84.6 95.1 8.20E-04 (I)
HPN{ 4054 3284 3041 2546 8.23E-03 (I)
IFN-a 34.1 43.6 20.5 13.9 1.89E-03 (I)
IL-11 278 163 146 145 9.97E-06 (I)
IL-29/IFNl1 284 193 200 100 6.97E-04 (I)
IP-10 98.2 96.0 60.2 53.4 1.48E-03 (I)
MCP-2 71.3 56.1 53.5 35.8 8.32E-03 (I)
M-CSF 317 554 86.8 250 2.45E-03 (I)
MIP-1d 3720 2267 2816 1941 8.05E-03 (I)
MMP-9{ 81.0 76.5 128 133 5.88E-03 (D)
OC 3811 2644 4536 2808 7.79E-03 (D)
SAA{ 591 3361 295 462 9.69E-03 (I)
SAP{ 4934 1962 3647 1207 2.69E-04 (I)
sIL-1R1 26.8 15.7 21.1 8.10 7.37E-03 (I)
TIMP-1{ 160 50.6 137 33.8 4.57E-03 (I)
A1A{ 1769 2124 1062 810 3.28E-03 (I)
IQR – interquartile range; MWU - Mann Whitney U test with 5% False Discovery Rate; Biomarkers in bold represent consensus markers also selected by parametric
statistics;
{values expressed in ng/ml, all others expressed in pg/ml; Trends: I – increased in A-NHL group, D – decreased in A-NHL group.
doi:10.1371/journal.pone.0099144.t003
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experimental treatment for hematological malignancies [37].
CXCL11 is a chemokine known to mediate the migration of
activated T-cells, and has been described as an immunomodula-
tory target of miRNA in primary lymphoma and has also
demonstrated potent antitumor activity in an animal model
[38,39]. The type III interferon IL-29 is the focus of considerable
interest in the setting of hepatitis C viral infection and was recently
shown to impede HIV-1 infection in T-cells [40,41]. A role in the
development of A-NHL for IL-29 has not yet been described.
A number of additional proteins with varying biological
functions but unifying roles in inflammation and immune
activation were also associated with A-NHL in univariate analyses
in the current study, but were not statistically significant after
Bonferroni correction. In such a broad survey, this is not
unexpected, but the data does confirm previous reports of some
of these proteins being associated with inflammatory processes
around the time of A-NHL or NHL diagnosis. Several of the
chemoattractant proteins (CCL19/MIP-3b, MCP-2, CXCL9/
Table 4. Conditional Logistic Regression Analyses with Bonferroni Step-down Adjustment of Serum Biomarker Levels of AIDS-NHL
and control subjects.
Biomarker A-NHL (n =46) Controls (n=46) Exact p-value Bonferroni Adjusted p-value
Mean SD Mean SD
ApoA1 1267 252 1374 213 0.0111 NS
CA 19-9 4.97 26.9 0.490 0.197 0.0013 NS
CCL19/MIP-3b 648 2777 196 77.5 0.0025 NS
CCL20/MIP-3a 47.2 188 11.5 7.51 0.0056 NS
C3 111 47.3 81.9 30.3 0.0003 NS
CFH 559 169 473 94.8 0.0016 NS
CXCL11/I-TAC 436 535 175 151 0.0001 0.017
CXCL6/GCP-2 342 1362 114 51.7 0.0138 NS
CCL11 212 145 190 70.7 0.0061 NS
G-CSF 176 325 73.8 71.9 0.0023 NS
HPN{ 5110 4037 3148 2284 0.0093 NS
I-309 11.3 29.9 3.39 3.52 0.0126 NS
IFNa 13365 87796 65.5 189 0.0407 NS
IGFBP-3{ 1524 248 1420 328 0.0085 NS
IGFBP-5{ 120 72.6 90.8 58.3 0.0124 NS
IGFBP-6{ 149 42.0 169 64.0 0.0274 NS
IL-11 5663 36435 176 97.9 ,0.0001 ,0.017
IL-20 115 253 56.8 34.3 0.0177 NS
IL-28A 555 3128 16.0 20.4 0.0249 NS
IL-29 11685 76491 232 127 0.0001 0.017
IL-7 49.7 146 18.4 7.37 0.0066 NS
IP-10 130 93.0 86.8 91.4 0.0173 NS
MCP-2 88.0 66.9 61.5 36.1 0.025 NS
M-CSF 15887 105262 277 405 0.0065 NS
MIF 964 2916 246 181 0.0402 NS
MIP-1d 5617 7942 3295 2265 0.0056 NS
MIP-4{ 22.2 19.4 16.0 7.88 0.0205 NS
MMP-3{ 57.5 163 18.1 7.30 0.0453 NS
MMP-9{ 108 94.1 154 103 0.0171 NS
OC 3996 2421 5375 3116 0.006 NS
PEDF{ 1777 424 1604 339 0.0379 NS
SAA{ 18574 67358 582 1020 0.0008 NS
SAP{ 4759 1623 3867 1307 0.004 NS
SCGF-B{ 60.3 49.4 45.9 15.7 0.0464 NS
sIL-1RI 45.2 106 24.3 8.43 0.0041 NS
sTNF-RII{ 10.5 4.56 8.43 3.56 0.0172 NS
TIMP-1{ 199 174 148 40.4 0.0096 NS
SD – standard deviation, NS - non-significant;
{concentration expressed as ng/ml, all others expressed in pg/ml; Biomarkers in bold represent consensus markers also selected by non-parametric statistics.
doi:10.1371/journal.pone.0099144.t004
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MIG) have been reported to have an association with various
forms of leukemia and lymphoma [42,43], 41. Of particular
interest for A-NHL is IP-10, a leukocyte chemoattractant
implicated in the development and progression of B-cell lympho-
ma. In two recent studies, elevated levels of IP-10 in the sera of
HIV-positive individuals were associated with the development of
B-cell lymphoma within 0–5 years 22, [44]. Elevated pretreatment
serum levels of IP-10 were also associated with increased likelihood
of disease relapse and diminished survival in HIV-uninfected
patients with diffuse large B-cell lymphoma [45]. The gelatinase
MMP-9 and its inhibitor TIMP-1 mediate breakdown of the
extracellular matrix during inflammatory and other responses, and
one or both have been linked to lymphoma at the time of diagnosis
[46] [47,48]. The acute phase protein, SAA has been shown to be
overexpressed in B-cell NHL associated with SIV infection in
monkeys [49], and complement components (C3 and CR2) may
be involved in lymphomagenesis and/or complement activation
[50], [51]. IFNa is currently under investigation as a potential
therapeutic agent in lymphoma, including A-NHL, stemming
from its ability to mediate apoptosis in malignant cells[52–54].
Biological roles related to the development of lymphoma have
not been conclusively described for MIP-1d, M-CSF, sIL-1R1,
HPN, SAP, and OC and, to the best of our knowledge, we are the
first to report on these associations. Each of these proteins does
possess functions relating them to inflammation and were linked
mechanistically to other potential biomarkers in our pathway
analysis. Further investigation into the precise activity of each of
these proteins in lymphoma would be of great interest.
Many of the biomarkers found to be significantly altered in A-
NHL subjects appear to be positively associated with HIV disease
progression, as indicated by their observed correlation with HIV
viral load (Table 5). Each of the biomarkers found to be positively
correlated with viral load were also observed to be elevated in the
sera of A-NHL cases in comparison to the controls. As CD4 count
was included in our matching criteria and was not significantly
different between the two experimental groups, we propose that
varying degrees of control of HIV (or lack thereof) within each
experimental group, as opposed to among the groups, led to our
observations. These observations are in line with the hypothesis
that increases in HIV viral burden result in elevated levels of
immune stimulation and inflammation which then promotes NHL
pathogenesis. Based on these findings, we may also hypothesize
that HIV-driven alterations in immune response are augmented in
A-NHL, a phenomenon that warrants additional investigation. In
contrast to other biomarkers, higher MMP-9 levels correlated with
lower viral load and control (non-malignancy) status. A direct
relationship between increased MMP-9 activity and immune
competence and/or protection from lymphoma has not been
described, leading us to speculate that the relationship between
MMP-9 and A-NHL may be a protective one which warrants
further exploration.
When A-NHL subjects of differing disease subtypes were
evaluated separately, relatively few significant alterations were
found. Several biomarkers including OC, SAP, and Timp-1 were
found to be significantly elevated in CNS NHL in comparison to
other subtypes. To the best of our knowledge, we are the first to
report on such associations. For the vast majority of the
biomarkers examined, we were not able to detect any significant
differences between NHL subtypes, although this may be due to
the relatively small sample size of each subset and the amount of
variability within both case and control groups. Our results are
similar to the recent findings of Breen et al. in which no significant
differences were observed when comparing biomarker levels of
diffuse large B cell cases to BL cases; however, in that study all
significantly increased biomarker levels in cases compared to
controls were associated with the systemic form of NHL but not
CNS NHL [21]. While utilizing many of the same MACS A-NHL
cases, the current investigation in general examined different time
points (closer to or after NHL diagnosis), and each study evaluated
a distinct set of biomarkers.
The results of the pathway analysis indicate the existence of a
complex network of interactions among the collective list of
biomarkers identified in the current and previous investigations.
An examination of this network suggests central roles for two
previously identified biomarkers, IL-6 and IL-10 (Figure 1).
Several newly identified biomarkers including MMP-9, IP-10,
and M-CSF also appear to play central roles. Each of the three
biomarkers demonstrating the strongest associations with A-NHL
in the current study (IL-11, CXCL11, and IL-29) were found to
interact with biomarkers from both the current and previous
reports. In the course of further development of potential A-NHL
biomarkers, many candidate proteins are likely to be eliminated
based on technical and/or biological limitations. A more complete
understanding of the network of interactions displayed in this
analysis should enable us to more effectively identify potential
alternatives to those biomarkers which work in close proximity
within disease processes.
Table 5. Spearman Correlations of Consensus Biomarkers and HIV Load among all subjects.*
Biomarker Spearman r p
CCL19/Mip-3b 0.67 0.0001
CXCL11/I-TAC 0.52 0.0001
IL-11 0.50 0.0001
IP-10 0.46 0.0003
MCP-2 0.42 0.001
IFN-a 0.42 0.0011
M-CSF 0.41 0.0013
SAP 0.40 0.0019
MMP-9 20.38 0.0029
*Analysis included all subjects with available HIV load measurement (n = 58).
doi:10.1371/journal.pone.0099144.t005
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In the current study, an analysis of a broad array of circulating
proteins yielded a relatively small but robust collection of
inflammatory mediators associated with the development of A-
NHL in comparison to controls. Many of the identified biomarkers
were positively correlated to HIV viral load and indicate
heightened immune responses in A-NHL with respect to HIV
infection and/or AIDS in the absence of lymphoma. A minority of
the subjects included in the current study were former or current
recipients of HAART. Although the distribution of HAART
recipients was similar among cases and controls, we cannot rule
out some effect of treatment on our biomarker findings. Our
findings further support the hypothesis that A-NHL develops in
response to persistent immune activation and inflammation and
adds new points of focus for further investigation. Ongoing
analysis into the precise role of each of the biomarkers identified in
our report should enhance our ability to diagnose, monitor and
treat this disease.
Figure 1. A-NHL biomarker pathway analysis. The Ingenuity Pathway Analysis (IPA) software package was utilized to identify pathways and
specific interactions associated with the serum biomarkers identified in the current and previous reports. Biomarkers evaluated from the current
study (rectangles) included CCL19, CXCL11, MCP-2, MIP-1d, IFN-a, IL-11, IL-29, IP-10, M-CSF, sIL-1R1, C3, HPN, SAA, SAP, MMP-9, TIMP-1 and OC.
Biomarkers evaluated based on previous findings (ovals) included IL-6, sCD30, IL-10, sCD23, sCD44, sCD27, CRP, BCA-1/CXCL13 and IgE. Solid lines
indicate direct interactions, dashed lines indicate indirect interactions.
doi:10.1371/journal.pone.0099144.g001
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